Fig. 2From: Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohortGeographic prevalence of antibodies against SARS-CoV-21 in people living in France2 at the end of the first lockdown: the national EpiCov cohort, round 1—May 2020Back to article page